Cargando…
Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection
Globally, chronic hepatitis B (CHB) infection is one of the leading causes of liver failure, decompensated cirrhosis, and hepatocellular carcinoma. Existing antiviral therapy can suppress viral replication but not fully eradicate the virus nor the risk of liver-related complications. Novel treatment...
Autores principales: | Mak, Lung-Yi, Seto, Wai-Kay, Yuen, Man-Fung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235765/ https://www.ncbi.nlm.nih.gov/pubmed/34207458 http://dx.doi.org/10.3390/v13061169 |
Ejemplares similares
-
RNA interference as a novel treatment strategy for chronic hepatitis B infection
por: Hui, Rex Wan-Hin, et al.
Publicado: (2022) -
New Biomarkers of Chronic Hepatitis B
por: Mak, Lung-Yi, et al.
Publicado: (2019) -
Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety
por: Lam, Yuk-Fai, et al.
Publicado: (2011) -
First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients
por: Mak, Lung-Yi, et al.
Publicado: (2021) -
Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment
por: Cheung, Ka-Shing, et al.
Publicado: (2017)